Rchr
J-GLOBAL ID：200901080605111965
Update date: Sep. 06, 2024
Yanagisawa Kiyoshi
ヤナギサワ キヨシ | Yanagisawa Kiyoshi
Affiliation and department：
Research theme for competitive and other funds (16)：
- 2021 - 2024 悪性胸膜中皮腫を対象とする新たな分子標的治療法開発
- 2018 - 2021 Clinical proteomics for deveolpment of novel therapy of malignant pleural mesothelioma
- 2015 - 2020 Systems analysis of roles of non-coding RNAs in lung cancer development
- 2013 - 2017 Development of novel molecular diagnosis methods of lung cancer by proteomic signature
- 2013 - 2017 Development of novel molecular diagnosis and therapy of malignant pleural mesothelioma
- 2013 - 2016 ROR1 sustains RTK-mediated survival signaling in lung adenocarcinoma
- 2013 - 2016 Roles of TTF-1/NKX2-1 lineage-survival oncogene in lung adenocarcinoma
- 2010 - 2016 Scientific Support Programs for Cancer Research Grant-in-Aid for Scientific Research on Innovative Areas
- 2010 - 2012 molecular signature for detection of intractable tumors
- 2009 - 2011 MRM・MS and microRNA profiling analyses of blood samples and their clinical applications for development of molecular diagnostics
- 2005 - 2009 Molecular dissection of molecular pathogenesis of lung cancer towards realization of personalized medicine
- 2007 - 2008 Comprehensive protein expression profiling using proteomic technologies to explorer lung cancer associated molecules
- 2006 - 2008 Tailor-made cancer diagnosis by systematically detecting alterations of miRNA and protein expressions
- 2005 - 2006 イメージングマスによる肺癌及び特発性肺線維症の発症・進展の分子機構に関する検討
- 2003 - 2005 Integrated system of the tailor-made cancer treatment based on the expression profiling and bioinformatic analyses
- 2000 - 2004 Multifaceted analysis of molecular pathogenesis of human lung cancers
Show all
Papers (36)：
-
Akira Tazaki, Delgama A.S.M. Nishadhi, Ao Li, Lanyue Zhang, Than Htike Maw, Lisa Kondo-Ida, Kiyoshi Yanagisawa, Masashi Kato. Progression from in vivo validation to in vitro screening in hazard assessment for leukoderma-inducible chemicals. Environmental Pollution. 2024. 356. 124508-124508
-
Mika Iwai, Taisuke Kajino, Masahiro Nakatochi, Kiyoshi Yanagisawa, Yasuyuki Hosono, Hisanori Isomura, Yukako Shimada, Motoshi Suzuki, Ayumu Taguchi, Takashi Takahashi. Long non-coding RNA TILR constitutively represses TP53 and apoptosis in lung cancer. Oncogene. 2023
-
Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF-1α regulator. Cancer Science. 2021. 112. 4. 1614-1623
-
Lithium promotes malignant transformation of nontumorigenic cells in vitro. Science of the Total Environment. 2020. 744
-
Motoshi Suzuki, Ke Cao, Seiichi Kato, Naoki Mizutani, Kouji Tanaka, Chinatsu Arima, Mei Chee Tai, Norie Nakatani, Kiyoshi Yanagisawa, Toshiyuki Takeuchi, et al. CERS6 required for cell migration and metastasis in lung cancer. Journal of Cellular and Molecular Medicine. 2020. 24. 20. 11949-11959
ｍore...
MISC (25)：
-
長田 啓隆, 柳澤 聖, 関戸 好孝, 島村 徹平, 宮野 悟, 高橋 隆. 肺癌発症におけるASH1シグナル下流のIncRNAの役割の検討. 日本癌学会総会記事. 2016. 75回. E-2119
-
Tomoya Yamaguchi, Can Lu, Lisa Ida, Kiyoshi Yanagisawa, Jiro Usukura, Jinglei Cheng, Naoe Hotta, Yukako Shimada, Hisanori Isomura, Motoshi Suzuki, et al. ROR1 sustains caveolae and RTK-mediated survival signaling as a scaffold of cavin-1 and CAV1 in lung cancer. CANCER RESEARCH. 2016. 76
-
長田 啓隆, 柳澤 聖, 立松 義朗, 関戸 好孝, 小野 健一郎, 高橋 隆. 分子標的治療を目指す転移関連遺伝子CLCP1に対する抗体FA19-1による解析. 日本癌学会総会記事. 2015. 74回. E-1017
-
長田 啓隆, 柳澤 聖, 立松 義朗, 関戸 好孝, 高橋 隆. CRISPR-Cas9による遺伝子ノックアウトを用いた転移関連遺伝子CLCP1の機能解析(CRISPR-Cas9-derived Knockout of CLCP1 gene revealed its functional role in lung cancer progression). 日本癌学会総会記事. 2014. 73回. E-1027
-
長田 啓隆, 八木 香澄, 柳澤 聖, 赤塚 淳一, 立松 義朗, 加藤 省一, 谷田部 恭, 小野 健一郎, 関戸 好孝, 高橋 隆. 転移関連分子CLCP1の機能解析と診断治療への応用の検討(Functional analysis of CLCP1 as potential target for lung cancer diagnostics and therapeutics). 日本癌学会総会記事. 2013. 72回. 101-101
ｍore...
Professional career (1)：
Return to Previous Page
